Table 2.

Summary of safety in ETV-060: switch cohort

On-treatment in ETV-060	Patients, n (%)
Any adverse events	33 (100)
Clinical adverse events	33 (100)
Laboratory adverse events	33 (100)
Grade 3/4 clinical adverse event	1 (3)
Grade 3/4 laboratory adverse event	5 (15)
Clinical serious adverse eventa	3 (9)
Discontinuations due to adverse events	1 (3)
Deaths	0
ALT flaresb	1 (3)

^aIncluding ALT flares

^bALT >2 × baseline and >10 × ULN